Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.
Foxwell
B
B
The Kennedy Institute of Rheumatology Division, Imperial College London, The Charing Cross Campus, ARC Building, 1 Aspenlea Road, London W6 8LH, UK. b.foxwell@imperial.ac.uk
Andreakos
E
E
Brennan
F
F
Feldmann
M
M
Smith
C
C
Conron
M
M
D018501:Antirheumatic Agents / Q000737:chemistry / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D015195:Drug Design; D006801:Humans; D008970:Molecular Weight; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha